Read the target-to-patient map
Classify a biotech program by its current drug-development stage and the evidence that should exist there.
The move: place the claim before you rate the claim. Biotech progress is not one straight proof line. It is a sequence of gates with different questions. In discovery, the team is still proving that the biology, target, modality, assay, and disease rationale belong together. In preclinical research, the team must turn that biology into evidence that supports human testing. In clinical research, the question shifts to people: dose, safety, efficacy, endpoints, population, and comparator. The FDA process is useful because it separates enthusiasm from evidence. A mouse result can justify more work, but it does not answer whether a…
Sign up free — one personalized lesson every day, matched to your role and goals.
Already have an account? Sign in